{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T02:08:39Z","timestamp":1780625319629,"version":"3.54.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.eplepsyres.2017.12.006","type":"journal-article","created":{"date-parts":[[2017,12,5]],"date-time":"2017-12-05T23:07:58Z","timestamp":1512515278000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Divergent effects of levetiracetam and tiagabine against spontaneous seizures in adult rats following neonatal hypoxia"],"prefix":"10.1016","volume":"140","author":[{"given":"Raymond","family":"Dunn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget N.","family":"Queenan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel T.S.","family":"Pak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Forcelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0005","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0306-4522(91)90380-7","article-title":"Synaptic reorganization by mossy fibers in human epileptic fascia dentata","volume":"42","author":"Babb","year":"1991","journal-title":"Neuroscience"},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0010","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2147\/NDT.S833","article-title":"Tiagabine: efficacy and safety in partial seizures \u2212 current status","volume":"4","author":"Bauer","year":"2008","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0015","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1528-1157.1984.tb04168.x","article-title":"Neonatal hypoxia and epileptic risk: a clinical prospective study","volume":"25","author":"Bergamasco","year":"1984","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0020","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.seizure.2004.02.001","article-title":"Effects of levetiracetam on spike and wave discharges in WAG\/Rij rats","volume":"13","author":"Bouwman","year":"2004","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0025","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0920-1211(95)00015-3","article-title":"Effects of the GABA-uptake inhibitor tiagabine on electroencephalogram, spike-wave discharges and behaviour of rats","volume":"21","author":"Coenen","year":"1995","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0030","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0304-3940(97)00423-0","article-title":"Tiagabine exerts an anti-epileptogenic effect in amygdala kindling epileptogenesis in the rat","volume":"229","author":"Dalby","year":"1997","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0035","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0920-1211(97)00031-4","article-title":"Comparison of the preclinical anticonvulsant profiles of tiagabine, lamotrigine, gabapentin and vigabatrin","volume":"28","author":"Dalby","year":"1997","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0040","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.expneurol.2014.12.010","article-title":"Optimized methods for epilepsy therapy development using an etiologically realistic model of focal epilepsy in the rat","volume":"264","author":"Eastman","year":"2015","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0045","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/j.1528-1157.1999.tb00835.x","article-title":"Two cases of nonconvulsive status epilepticus in association with tiagabine therapy","volume":"40","author":"Ettinger","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0050","first-page":"8","article-title":"Delayed effect of craniotomy on experimental seizures in rats","author":"Forcelli","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0055","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1046\/j.1528-1157.2001.042suppl.3042.x","article-title":"Tiagabine in clinical practice","volume":"42","author":"Genton","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0060","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0014-2999(93)90582-3","article-title":"ucb L059, a novel anti-convulsant drug: pharmacological profile in animals","volume":"230","author":"Gower","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0065","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0920-1211(95)00077-1","article-title":"Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy","volume":"22","author":"Gower","year":"1995","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0070","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0014-2999(95)00835-7","article-title":"Tiagabine prevents seizures, neuronal damage and memory impairment in experimental status epilepticus","volume":"299","author":"Halonen","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0075","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/(SICI)1096-9861(19990222)404:4<537::AID-CNE9>3.0.CO;2-#","article-title":"Mossy fiber sprouting after recurrent seizures during early development in rats","volume":"404","author":"Holmes","year":"1999","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0080","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0920-1211(99)00029-7","article-title":"Activity-dependent enhancement of hyperpolarizing and depolarizing gamma-aminobutyric acid (GABA) synaptic responses following inhibition of GABA uptake by tiagabine","volume":"37","author":"Jackson","year":"1999","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0085","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1152\/jn.1999.81.3.1192","article-title":"Inhibitory nature of tiagabine-augmented GABAA receptor-mediated depolarizing responses in hippocampal pyramidal cells","volume":"81","author":"Jackson","year":"1999","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0090","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/ana.410290610","article-title":"Epileptogenic effect of hypoxia in the immature rodent brain","volume":"29","author":"Jensen","year":"1991","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0095","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/j.1528-1157.1995.tb00954.x","article-title":"NBQX blocks acute and late epileptogenic effects of perinatal hypoxia","volume":"36","author":"Jensen","year":"1995","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0100","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0014-2999(98)00410-5","article-title":"Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy","volume":"353","author":"Klitgaard","year":"1998","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0105","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1528-1167.2001.00003.x","article-title":"Levetiracetam: the preclinical profile of a new class of antiepileptic drugs?","volume":"42","author":"Klitgaard","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0110","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1053\/seiz.1999.0303","article-title":"Tiagabine-induced absence status in idiopathic generalized epilepsy","volume":"8","author":"Knake","year":"1999","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0115","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0120","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0014-2999(93)90768-D","article-title":"Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats","volume":"232","author":"L\u00f6scher","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0125","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.seizure.2011.01.003","article-title":"Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs","volume":"20","author":"L\u00f6scher","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0130","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eplepsyres.2016.05.016","article-title":"Fit for purpose application of currently existing animal models in the discovery of novel epilepsy therapies","volume":"126","author":"L\u00f6scher","year":"2016","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0135","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1111\/epi.12378","article-title":"AMPA Receptor antagonist NBQX attenuates later-life epileptic seizures and autistic-like social deficits following neonatal seizures","volume":"54","author":"Lippman-Bell","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0140","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1111\/j.1528-1157.1999.tb02089.x","article-title":"Review of controlled trials of gabitril (Tiagabine): a clinician\u2019s viewpoint","volume":"40","author":"Loiseau","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0145","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0150","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.eplepsyres.2010.08.002","article-title":"Patterns of prescription of antiepileptic drugs in patients with refractory epilepsy at tertiary referral centres in Italy","volume":"91","author":"Malerba","year":"2010","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0155","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.lfs.2003.08.006","article-title":"Levetiracetam protects against kainic acid-induced toxicity","volume":"74","author":"Marini","year":"2004","journal-title":"Life Sci."},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0160","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1124\/jpet.113.203331","article-title":"Synergistic GABA-Enhancing therapy against seizures in a mouse model of dravet syndrome","volume":"345","author":"Oakley","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0165","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nrneurol.2009.80","article-title":"Epileptogenesis in the immature brain: emerging mechanisms","volume":"5","author":"Rakhade","year":"2009","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0170","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1528-1167.2011.02992.x","article-title":"Development of later life spontaneous seizures in a rodent model of hypoxia-induced neonatal seizures","volume":"52","author":"Rakhade","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0175","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.pharep.2014.11.003","article-title":"Anticonvulsant active inhibitor of GABA transporter subtype 1, tiagabine, with activity in mouse models of anxiety, pain and depression","volume":"67","author":"Salat","year":"2015","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0180","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1046\/j.1528-1157.2001.01600.x","article-title":"Status epilepticus and tiagabine therapy: review of safety data and Epidemiologic\u2003Comparisons","volume":"42","author":"Shinnar","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0185","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.nbd.2015.12.012","article-title":"Optogenetic activation of superior colliculus neurons suppresses seizures originating in diverse brain networks","volume":"87","author":"Soper","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0190","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1073\/pnas.1208010110","article-title":"Mammalian target of rapamycin complex 1 activation negatively regulates Polo-like kinase 2-mediated homeostatic compensation following neonatal seizures","volume":"110","author":"Sun","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0195","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jneumeth.2015.09.023","article-title":"Models of hypoxia and ischemia-induced seizures","volume":"260","author":"Sun","year":"2016","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0200","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1528-1157.1995.tb02576.x","article-title":"A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor","volume":"36","author":"Suzdak","year":"1995","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0205","first-page":"73","article-title":"Antiepileptic effects of levetiracetam in a rodent neonatal seizure model","volume":"24","author":"Talos","year":"2013","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0210","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/j.1528-1167.2007.01120.x","article-title":"Typical versus atypical absence seizures: network mechanisms of the spread of paroxysms","volume":"48","author":"Velazquez","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0215","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1124\/mol.111.076687","article-title":"The synaptic vesicle glycoprotein 2A ligand levetiracetam inhibits presynaptic Ca2+ channels through an intracellular pathway","volume":"82","author":"Vogl","year":"2012","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2017.12.006_bib0220","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.neuropharm.2009.12.007","article-title":"Intravenous levetiracetam in the rat pilocarpine-induced status epilepticus model: behavioral, physiological and histological studies","volume":"58","author":"Zheng","year":"2010","journal-title":"Neuropharmacology"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121117305004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121117305004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:37:51Z","timestamp":1760276271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121117305004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":44,"alternative-id":["S0920121117305004"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2017.12.006","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Divergent effects of levetiracetam and tiagabine against spontaneous seizures in adult rats following neonatal hypoxia","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2017.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}